Ryan J. Watts
Denali Therapeutics (United States) · 108 works · 16,257 citations · h-index 53
Top works
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
- Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
- Therapeutic antibody targeting of individual Notch receptors
- Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth
- Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
- The Drosophila Cell Corpse Engulfment Receptor Draper Mediates Glial Clearance of Severed Axons
- Axon Pruning during Drosophila Metamorphosis
- Engaging neuroscience to advance translational research in brain barrier biology
- Involvement of the Ubiquitin-Proteasome System in the Early Stages of Wallerian Degeneration
- Blocking Neuropilin-2 Function Inhibits Tumor Cell Metastasis
- TREM2 Regulates Microglial Cholesterol Metabolism Upon Chronic Phagocytic Challenge
- A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
- Wlds Protection Distinguishes Axon Degeneration following Injury from Naturally Occurring Developmental Pruning
- Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
- Glia Engulf Degenerating Axons during Developmental Axon Pruning
- Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
- Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
- VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis
- Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants
- Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice